HanxBio announces the publication of a research paper in Scientific Reports on preclinical evaluation of Narazaciclib for the treatment of acute myeloid leukemia (AML)
Narazaciclib (HX301 or ON123300) is a clinical stage small molecule investigational new drug jointly developed by HanxBio and its business partner OncoNova Therapeutics, Inc. (now Traws Pharma, Inc.).
- Narazaciclib (HX301 or ON123300) is a clinical stage small molecule investigational new drug jointly developed by HanxBio and its business partner OncoNova Therapeutics, Inc. (now Traws Pharma, Inc.).
- In this peer-reviewed article, the researchers from HanxBio described comprehensive pharmacology characterization of HX301 using a series of preclinical experimental AML models, including in vitro cell lines, and in vivo cell line-derived xenografts (CDXs) and patient-derived xenografts (PDXs).
- This report also studied the pharmacodynamics and pharmacokinetics of HX301, including the relationship between drug exposure and efficacy, which can be used to assist clinical dosage selection.
- The results of this study will guide our clinical development strategies for HX301 for the treatment of AML."